In a new TV commercial for Takeda and Lundbeck’s depression medicine Trintellix, the lead actor turns to the camera and admits, “I don’t got this.”

The new direct-to-consumer campaign called “Real Talk” continues the marketers’ ongoing theme to reinforce that depression is “more than just sadness” and includes multiple overlapping symptoms depending on the patient.

The effort is built on patient research that uncovered a key insight that “patients have a difficult time describing their symptoms beyond feeling sad,” a Takeda spokesperson said.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN

People dealing with chronic or serious health conditions still want to live a full life. Bristol Myers Squibb teamed up with storytelling agency Human to showcase the “tenacious desire to live” among different people living with health conditions or diseases through an original documentary film.

Called “Living,” the patients shown in the unscripted film don’t have the same conditions or demographic profiles or even live in the same countries. There are six different people who do have one thing in common, though — they’re dealing with life-altering diseases. Five women and one man with different kinds of cancers, autoimmune diseases, and lung or cardiovascular conditions speak to the camera about their very personal experiences and emotions.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN

It’s no surprise that patient influencers are talking about their health conditions on social media. However, what’s less clear is what role pharma companies are playing, how big the patient influencer industry is, and just how is information about prescription drugs from influencers relayed — and received — on social media.

While University of Colorado associate professor Erin Willis can’t answer all those questions, she’s been researching the issue for several years and recently published new research digging into the communication styles, strategies and thinking of patient influencers, many of whom partner with pharma companies.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN

The UK’s Medicines and Healthcare products Regulatory Agency is now reviewing Novo Nordisk’s marketing violation that resulted in its loss of UK trade group membership last week. Novo Nordisk was suspended on Thursday from the Association of the British Pharmaceutical Industry (ABPI) for two years after an investigation by its regulatory arm found the pharma broke its conduct rules.

MHRA said on Tuesday that its review of the Prescription Medicines Code of Practice Authority (PMCPA) investigation is standard practice. An MHRA spokesperson emphasized in an email to Endpoints News that the situation with Novo Nordisk is “incredibly rare” while also noting ABPI took “swift and proportionate action.”

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN

Just as pharma marketers finally make moves into TikTok, the threat of a US ban on the social media channel is now looming. Already banned on federal employee phones by an initial Congressional act, more bills and maybe bans are on the way. With rare bipartisan agreement, lawmakers have introduced legislation that would give the US president the power to ban TikTok (although not mentioned by name) and other foreign-owned technology platforms that represent a security threat to the US.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN

What do you get when you combine ChatGPT generative AI technology with specific pharma and clinical datasets? A time-saving tool that can answer questions about medical conference abstracts and clinical findings in seconds in one new application from ZoomRx called FermaGPT.

ZoomRx is debuting a public version of its generative AI product specifically for medical conferences beginning this week for the upcoming American Association for Cancer Research (AACR) annual meeting that runs April 14-19.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN

AbbVie turns 10 this year, and a new corporate campaign is tapping employees to highlight the decade of accomplishments.

Labeled with an “AbbVie 10” logo, the social media and digital work includes real employees from around the world talking about why they like working there, what they’re proud of and what the future holds. AbbVie kicked off the campaign behind the scenes in January by asking employees to share memories of the past decade, and they came through with stories, photos and videos, AbbVie told Endpoints News. It then created a feature story on its website with a compilation video of various employees. Social posts are running on LinkedIn, Facebook, Instagram and Twitter.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN

Novo Nordisk’s type 2 diabetes treatment Ozempic, which is also used off-label for weight loss, is back in stock following a months-long shortage, according to the FDA’s drug shortages list.

The FDA updated its website on Friday to show that Ozempic’s 0.25 mg, 0.5 mg and 1 mg doses are now available across the US. The 0.25 mg and 0.5 mg doses suffered limited supply for the last few months, according to a Novo Nordisk spokesperson. However, the 2 mg dose has “limited availability and may not fully meet demand until the end of this month,” the company told Endpoints News on Monday.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN

When Tiffany Stout was first diagnosed with ovarian cancer in 2015, she didn’t immediately take in the fact that it was specifically the low-grade serous type. It wasn’t until she met with her doctor later and understood she had low-grade serous ovarian cancer (LGSOC), a rare disease that grows more slowly than the more common high-grade serous type, but that is also resistant to chemotherapy and highly recurrent.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN